NA-Semax-Amidate
Overview
Most stable and potent Semax variant.
Reported benefits
Maximum cognitive enhancement and neuroprotection
Protocols & dosing
Typical dosage: 300-600 mcg (daily).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
NA-Semax-Amidate is not currently FDA-approved for any indication. Effective April 22, 2026, the FDA removed NA-Semax-Amidate from Category 2 of its Section 503A bulk drug substances list after the original nominators withdrew their nominations. This removal lifts the prior “significant safety risk” designation but does not place NA-Semax-Amidate on the 503A Bulks List. Compounding pharmacies may prepare it with a valid physician prescription and pharmaceutical-grade API from an FDA-registered manufacturer. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review this substance at its July 23–24, 2026 public meeting. Removed from FDA Category 2 effective April 22, 2026. Selected for PCAC review Day 2 — July 24, 2026. PCAC agenda: DSIP (Emideltide), Semax, Epitalon. NOT currently on 503A Bulks List — requires physician Rx. Source: FDA Advisory Committee Calendar / Lengea Law, May 2026.
| Country | Status |
|---|---|
| United States | Category 2 removed — compounding permitted with Rx (as of Apr 22, 2026) |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Well-tolerated, potential overstimulation
References
No external sources have been catalogued for this article yet.
Related peptides
- Cerebrolysin — Neuroprotection, recovery
- Cortexin — Neuropeptide complex
- Dihexa — Potent cognitive enhancer
- FGL (Fibroblast Growth Loop) — NCAM mimetic
- Memantine — NMDA antagonist
- NSI-189 — Neurogenesis, depression